Valuation: PFIZER

Market Cap 143B 143B 125B 116B 107B 201B 13,727B 204B 1,383B 540B 6,749B 535B 524B 23,334B P/E 2026 *
12.7x
P/E 2027 * 13.2x
Enterprise Value 192B 192B 169B 157B 144B 270B 18,481B 274B 1,861B 727B 9,086B 720B 705B 31,414B EV / Sales 2026 *
3.11x
EV / Sales 2027 * 3.13x
Free-Float
59.06%
Yield 2026 *
6.88%
Yield 2027 * 6.95%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 60 02/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2007
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.57%+1.12%+48.03%+159.58% 1,057B
+1.58%+4.00%+55.20%+53.82% 624B
+0.72%+1.61%+35.50%+80.60% 454B
+1.60%+6.25%+33.95%+29.84% 341B
-0.60%+1.52%+35.68%+39.76% 297B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 215B
+1.45%+2.69%+21.90%+59.77% 201B
-0.58%-3.26%+14.75%+67.27% 162B
Average +0.59%+0.77%+25.88%+51.83% 401.55B
Weighted average by Cap. +0.74%+1.57%+35.55%+77.32%

Financials

2026 *2027 *
Net sales 61.75B 61.75B 54.23B 50.43B 46.28B 86.96B 5,946B 88.3B 599B 234B 2,923B 232B 227B 10,108B 59.37B 59.37B 52.15B 48.5B 44.5B 83.61B 5,718B 84.9B 576B 225B 2,811B 223B 218B 9,719B
Net income 10.63B 10.63B 9.33B 8.68B 7.97B 14.97B 1,023B 15.2B 103B 40.27B 503B 39.89B 39.03B 1,740B 10.27B 10.27B 9.02B 8.39B 7.7B 14.46B 989B 14.68B 99.59B 38.91B 486B 38.55B 37.71B 1,681B
Net Debt 49.36B 49.36B 43.36B 40.32B 37B 69.52B 4,754B 70.59B 479B 187B 2,337B 185B 181B 8,081B 43.17B 43.17B 37.91B 35.26B 32.35B 60.79B 4,157B 61.73B 419B 164B 2,044B 162B 159B 7,066B
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A